Clinical trial
GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With…
NCT00105079 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00105079 |
|---|---|
| Title | GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection |
| Official title | A 48-week, Randomized, Open-label, 2-arm Study to Compare the Efficacy of Saquinavir/Ritonavir Twice Daily (BID) Plus Emtricitabine/Tenofovir Once Daily (QD) Versus Lopinavir/Ritonavir BID Plus Emtricitabine/Tenofovir QD in Treatment-naïve Human Immunodeficiency Virus Type 1 (HIV-1) Infected… |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | saquinavir [Invirase], Lopinavir/ritonavir, Emtricitabine/tenofovir disoproxil fumarate, Ritonavir |
| Enrollment | 337 |
| Start date | Apr 1, 2005 |
| Primary completion | Aug 1, 2007 |
| Completion | Jul 1, 2008 |
| First posted | Mar 7, 2005 |
| Last update posted | Nov 2, 2011 |
| Countries | Canada, France, Puerto Rico, Thailand, United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: